Clofazimine: Current status and future prospects

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 2, 2012, Pages 290-298

  Cholo, Moloko C ^a   Steel, Helen C ^a   Fourie, P B ^a   Germishuizen, Willem A ^a   Anderson, Ronald ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Anti inflammatory activity; Leprosy; Lysophospholipids; Membrane destabilization; Mycobacteria; Potassium transporters; Reactive oxygen species; Redox cycling; Spray drying; T lymphocytes; Tuberculosis

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ARACHIDONIC ACID; CALCIUM CHANNEL; CLARITHROMYCIN; CLOFAZIMINE; CLOFAZIMINE DERIVATIVE; ETHAMBUTOL; ETRAVIRINE; GATIFLOXACIN; INTERLEUKIN 2; ISONIAZID; K 56; KANAMYCIN; LINEZOLID; MEMBRANE PHOSPHOLIPID; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; POTASSIUM CHANNEL KV1.3; PROSTAGLANDIN E2; PROTEINASE INHIBITOR; PROTIONAMIDE; PYRAZINAMIDE; REACTIVE OXYGEN METABOLITE; TETRAMETHYLPIPERIDYL DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ATYPICAL MYCOBACTERIOSIS; BACTERIAL OUTER MEMBRANE; BLEEDING; BLOOD BRAIN BARRIER; CHEMOTHERAPY INDUCED EMESIS; COMBINATION CHEMOTHERAPY; CONJUNCTIVA DISEASE; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PENETRATION; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; ENZYME ACTIVITY; EPIGASTRIC PAIN; ERYTHEMA NODOSUM LEPROSUM; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; IMMUNOSUPPRESSIVE ACTIVITYY; INTESTINE OBSTRUCTION; INTRACELLULAR SIGNALING; LEPROMATOUS LEPROSY; LIPOPHILICITY; LIPOSOMAL FORMULATION; LUNG TUBERCULOSIS; LYMPHOCYTE PROLIFERATION; MAXIMUM PLASMA CONCENTRATION; MEMBRANE DAMAGE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM SMEGMATIS; NANOSUSPENSION FORMULATION; NAUSEA; NONHUMAN; NUTRITIONAL INTOLERANCE; OXIDATION REDUCTION REACTION; PARTICLE SIZE; POTASSIUM TRANSPORT; RESPIRATORY CHAIN; REVIEW; SKIN DISCOLORATION; SPLEEN INFARCTION; SPRAY DRYING; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTI-INFLAMMATORY AGENTS; ANTITUBERCULAR AGENTS; CLOFAZIMINE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; LEPROSY; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84863415530     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr444     Document Type: Review

References (90)

1. Barry VC, Belton JG, Conalty ML et al. A new series of phenazine (rimino-compounds) with high anti-tuberculosis activity. Nature 1957; 179: 1013-5.
2. Browne SG, Hogerzeil LM. B663 in the treatment of leprosy. Preliminary report of a pilot trial. Lepr Rev 1962; 33: 6-10.
3. Dutta RK. Clofazimine and dapsone: a combination therapy in erythema nodosum leprosum syndrome. Lepr India 1980; 52: 252-9.
4. Imkamp FM. The treatment of corticosteroid-dependent lepromatous patients in persistent erythema nodosum leprosum with clofazimine. Lepr Rev 1973; 44: 127-30.
5. Imkamp FM. Clofazimine (Lamprene or B663) in lepra reactions. Lepr Rev 1981; 52: 135-40.
6. Anderson R. The immunopharmacology of antileprosy agents. Lepr Rev 1983; 54: 139-44.
7. Reddy VM, O'Sullivan JF, Gangadharam PR. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother 1999; 43: 615-23.
8. van Rensburg CE, Jooné GK, Sirgel FA et al. In vitro investigation of the antimicrobial activities of novel tetramethylpiperidine-substituted phenazines against Mycobacterium tuberculosis. Chemotherapy 2000; 46: 43-8.
9. Barry VC, Conalty ML. The antimycobacterial activity of B663. Lepr Rev 1965; 36: 3-7.
10. Drugs.com. Clofazimine. http://www.drugs.com/cons/clofazimine. html (1 July 2011, date last accessed).
11. Working Group on New TB Drugs. Riminophenazines. http://www. newtbdrugs.org/project.php (1 July 2011, date last accessed).
12. Yano T, Kassovska-Bratinova S, Teh JS et al. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 2011; 286: 10276-87.
13. WHO. WHO Model List of Essential Medicines, 17th Edition (Updated: March 2011). http://www.who.int/medicines/publications/essentialmedicines/en/(13 September 2011, date last accessed).
14. WHO. WHO Model List of Essential Medicines for Children, 3rd Edition (Updated: March 2011). http://www.who.int/medicines/publications/essentialmedicines/en/(13 September 2011, date last accessed).
15. Mukherjee JS, Rich ML, Socci AR et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363: 474-81.
16. Sansarricq H (ed). Multidrug Therapy Against Leprosy: Development and Implementation Over the Past 25 Years. Geneva: WHO, 2004. ISBN 92 4 159176 5.
17. Fortún J, Martín-Dávila P, Navas E et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005; 56: 180-5.
18. WHO. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis (Updated: 2011). http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf (13 September 2011, date last accessed).
19. Coyne KM, Pozniak AL, Lamorde M et al. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 2009; 23: 437-46.
20. Chaisson RE, Keiser P, Pierce M et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 1997; 11: 311-7.
21. Franzblau SG, O'Sullivan JF. Structure activity relationships of selected phenazines against Mycobacterium leprae in vitro. Antimicrob Agents Chemother 1988; 32: 1583-5.
22. Jagannath C, Reddy MV, Kailasam S et al. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular and in vivo studies. Am J Respir Crit Care Med 1995; 151: 1083-6.
23. van Ingen J, van der Laan T, Dekhuijzen R et al. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands. Int J Antimicrob Agents 2010; 35: 169-73.
24. Shen GH, Wu BD, Hu ST et al. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 2010; 35: 400-4.
25. van Rensburg CE, Jooné GK, O'Sullivan JF et al. Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids. Antimicrob Agents Chemother 1992; 36: 2729-35.
26. van Rensburg CE, van Straten AM. An in vitro investigation of the susceptibility of Enterococcus faecalis to clofazimine and B669. J Antimicrob Chemother 1994; 33: 356-8.
27. Huygens F, O'Sullivan JF, van Rensburg CE. Antimicrobial activities of seven novel tetramethylpiperidine-substituted phenazines against multiple drug-resistant Gram-positive bacteria. Chemotherapy 2005; 51: 263-7.
28. Oliva B, O'Neill AJ, Miller K et al. Anti-staphylococcal activity and mode of action of clofazimine. J Antimicrob Chemother 2004; 53: 435-40.
29. O'Neill AJ, Miller K, Oliva B et al. Comparison of assays for detection of agents causing membrane damage in Staphylococcus aureus. J Antimicrob Chemother 2004; 54: 1127-9.
30. Caminero JA, Sotgiu G, Zumla A et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-9.
31. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
32. Kaplan JE, Benson C, Holmes KH et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58: 1-207; quiz CE1-4.
33. van Ingen J, Simons S, de Zwaan R et al. Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010; 48: 2749-53.
34. Rastosi H, Goh KS, Horgen L et al. Synergistic activities of antituberculous drugs with cerulenin and trans-cinnamic acid against Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 1998; 21: 149-57.
35. Bulatovic VM, Wengenack NL, Uhl JR et al. Oxidative stress increases susceptibility of Mycobacterium tuberculosis to isoniazid. Antimicrob Agents Chemother 2002; 46: 2765-71.
36. van Deun A, Maug AK, Salim MA et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-92.
37. De Bruyn EE, Steel HC, van Rensburg EJ et al. The riminophenazines, clofazimine and B669, inhibit potassium transport in Gram-positive bacteria by a lysophospholipid-dependent mechanism. J Antimicrob Chemother 1996; 38: 349-62.
38. Steel HC, Matlola NM, Anderson R. Inhibition of potassium transport and growth of mycobacteria exposed to clofazimine and B669 is associated with a calcium-independent increase in microbial phospholipase A2 activity. J Antimicrob Chemother 1999; 44: 209-16.
39. Matlola NM, Steel HC, Anderson R. Antimycobacterial action of B4128, a novel tetramethylpiperidyl-substituted phenazine. J Antimicrob Chemother 2001; 47: 199-202.
40. Imlay J, Fridovich I. Exogenous quinones directly inhibit the respiratory NADH dehydrogenase in Escherichia coli. Arch Biochem Biophys 1992; 296: 337-46.
41. Malone AS, Chung YK, Yousef AE. Proposed mechanism of inactivating Escherichia coli O157:H7 by ultra-high pressure in combination with tert-butyl-hydroquinone. J Appl Microbiol 2008; 105: 2046-57.
42. Bopape MC, Steel HC, Cockeran R et al. Antimicrobial activity of clofazimine is not dependent on mycobacterial C-type phospholipases. J Antimicrob Chemother 2004; 53: 971-4.
43. Cholo MC, Boshoff HI, Steel HC et al. Effects of clofazimine on potassium uptake by a Trk-deletion mutant of Mycobacterium tuberculosis. J Antimicrob Chemother 2006; 57: 79-84.
44. Kagan VE. Tocopherol stabilizes membrane against phospholipase A, free fatty acids and lysophospholipids. Ann N Y Acad Sci 1989; 570: 121-35.
45. Baciu M, Sebai SC, Ces O et al. Degradative transport of cationic amphiphilic drugs across phospholipid bilayers. Philos Transact A Math Phys Eng Sci 2006; 364: 2597-614.
46. Steel HC, Cockeran R, Anderson R. Platelet-activating factor and lyso-PAF possess direct antimicrobial properties in vitro. APMIS 2002; 110: 158-64.
47. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 11: 537-44.
48. + uptake regulator TrkA controls membrane potential, pH homeostasis and multidrug susceptibility in Mycobacterium smegmatis. J Antimicrob Chemother 2011; 66: 1489-98.
49. Epand RM, Rotem S, Mor A et al. Bacterial membranes as predictors of antimicrobial potency. J Am Chem Soc 2008; 130: 14346-52.
50. Epand RM, Epand RF. Bacterial membrane lipids in the action of antimicrobial agents. J Pept Sci 2011; 17: 298-305.
51. Yawalkar SJ, Vischer W. Lamprene (clofazimine) in leprosy. Basic information. Lepr Rev 1979; 50: 135-44.
52. Schaad-Lanyi Z, Dieterle W, Dubois JP et al. Pharmacokinetics of clofazimine in healthy volunteers. Int J Lepr Other Mycobact Dis 1987; 55: 9-15.
53. O'Connor R, O'Sullivan JF, O'Kennedy R. The pharmacology, metabolism and chemistry of clofazimine. Drug Metab Rev 1995; 27: 591-614.
54. Mansfield RE. Tissue concentrations of clofazimine (B663) in man. Am J Trop Med Hyg 1974; 23: 1116-9.
55. van Rensburg CE, Anderson R, O'Sullivan JF. Riminophenazine compounds: pharmacology and anti-neoplastic potential. Crit Rev Oncol Hematol 1997; 25: 55-67.
56. Holdiness MR. Clinical pharmacokinetics of clofazimine. A review. Clin Pharmacokinet 1989; 16: 74-85.
57. Peters JH, Gordon GR, Murray JF et al. Mutagenic activity of antileprosy drugs and their derivatives. Int J Lepr Other Mycobact Dis 1983; 51: 45-53.
58. O'Sullivan JF, Franzblau SG, White KE. New clofazimine analogues: a structure activity study in vitro. Health Cooperation Papers 1992; 12: 191-7.
59. O'Connor R, O'Sullivan JF, O'Kennedy R. Determination of serum and tissue levels of phenazines including clofazimine. J Chromatogr B Biomed Appl 1996; 681: 307-15.
60. Lu Y, Zheng M, Wang B et al. Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation. Antimicrob Agents Chemother 2011; doi:10.1128/AAC.00699-11.
61. Krishnan TR, Abraham I. Improved aqueous dissolution of clofazimine from coevaporates using polyvinylmethyl ether/maleic anhydride copolymer. Drug Dev Ind Pharm 1991; 17: 1823-42.
62. Narang AS, Srivastava AK. Evaluation of solid dispersions of clofazimine. Drug Dev Ind Pharm 2002; 28: 1001-13.
63. Kailasam S, Wise DL, Gangadharam PR. Bioavailability and chemotherapeutic activity of clofazimine against Mycobacterium avium complex infections in beige mice following a single implant of a biodegradable polymer. J Antimicrob Chemother 1994; 33: 273-9.
64. Salem II, Steffan G, Düzgünes N. Efficacy of clofazimine-modified cyclodextrin against Mycobacterium avium complex in human macrophages. Int J Pharm 2003; 260: 105-14.
65. Adams LB, Sinha I, Franzblau SG et al. Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. Antimicrob Agents Chemother 1999; 43: 1638-43.
66. Mehta RT. Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection. Antimicrob Agents Chemother 1996; 40: 1893-902.
67. Peters K, Leitzke S, Diederichs JE et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother 2000; 45: 77-83.
68. Chen R, Tagawa M, Hoshi N et al. Improved dissolution of an insoluble drug using a 4-fluid nozzle spray-drying technique. Chem Pharm Bull 2004; 52: 1066-70.
69. Alanazi FK, El-Badry M, Ahmed MO et al. Improvement of albendazole dissolution by preparing microparticles using spray-drying technique. Sci Pharm 2007; 75: 63-79.
70. Paradkar A, Ambike AA, Jadhav BK et al. Characterization of curcumin-PVP solid dispersion obtained by spray drying. Int J Pharm 2004; 27: 281-6.
71. Pokharkar VB, Mandpe LP, Padamwar MN et al. Development, characterization and stabilization of amorphous form of a low Tg drug. Powder Technol 2006; 167: 20-5.
72. Sacchetti M, van Oort M. Spray-drying and supercritical fluid particle generation techniques. In: Hickey AJ, ed. Inhalation Aerosol: Physical and Bological Basis for Therapy. NY: Marcel Dekker, 1996; 337-84.
73. Edwards DA, Hanes J, Caponetti G et al. Large porous particles for pulmonary drug delivery. Science 1997; 276: 1868-71.
74. Garcia-Contreras L, Fiegel J, Telko MJ et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother 2007; 51: 2830-6.
75. Fiegel J, Garcia-Contreras L, Thomas M et al. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm Res 2008; 25: 805-11.
76. Tsapis N, Bennett D, Jackson B et al. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci USA 2002; 99: 12001-5.
77. Sung JC, Garcia-Contreras L, Verberkmoes JL et al. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob Agents Chemother 2009; 53: 1338-43.
78. Garcia-Contreras L, Sung JC, Muttil P et al. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob Agents Chemother 2010; 54: 1436-42.
79. O'Hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res 2000; 17: 955-61.
80. Sethuraman VV, Hickey AJ. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. AAPS Pharm Sci Tech 2002; 3: 7-16.
81. Sung JC, Padilla DJ, Garcia-Contreras L et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res 2009; 26: 1847-55.
82. Germishuizen WA, Cholo MC, Fourie PB et al. Reformulating clofazimine for pulmonary delivery in the treatment of MDR-TB. In: Proceedings of the Second TB Conference, Durban, South Africa, 2010. Paper no. 82.
83. Bezerra EL, Vilar MJ, da Trindade Neto PB et al. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52: 3073-8.
84. Ren YR, Pan F, Parvez S et al. Clofazimine inhibits human Kv 1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS ONE 2008; 3: e4009.
85. +-adenosine triphosphatase activity of human lymphocytes by a lysophospholipid-dependent mechanism. Biochem Pharmacol 1993; 46: 2029-38.
86. Segel GB, Lichtman M. Potassium transport in human blood lymphocytes treated with phytohemagglutinin. J Clin Invest 1976; 58: 1358-69.
87. Prasad KV, Severini A, Kaplan JG. Sodium ion influx in proliferating lymphocytes: an early component of the mitogenic signal. Arch Biochem Biophys 1987; 252: 515-25.
88. Airmid. Kv1.3 Potassium Channel. 2007. http://www.airmid.com/kv-potassium-channel.html (1 July 2011, date last accessed).
89. Zeis BM, Anderson R. Clofazimine-mediated stimulation of prostaglandin synthesis and free radical production as novel mechanisms of drug-induced immunosuppression. Int J Immunopharmacol 1986; 8: 731-9.
90. Anderson R, Beyers AD, Savage JE et al. Apparent involvement of phospholipase A2, but not protein kinase C, in the pro-oxidative interactions of clofazimine with human phagocytes. Biochem Pharmacol 1988; 37: 4635-41.